MS Active Source

Treatment

• Introduction
• Introduction to MS
• MS treatments
  • Intro to MS treatments
  • Interferons
  • Avonex
  • Betaferon
  • Rebif
  • Glatiramer acetate
  • Copaxone
  • Natalizumab
  • Tysabri
  • Treatment of relapses
  • Risk-sharing scheme
  • Progressive MS
• Positive approach
• Newly diagnosed?
• Relative with MS
• Links
• Principles of treatment

Rebif (Interferon Beta-1a) ( refT9 )

Rebif is given as a sc (subcutaneous) injection under the skin, three times a week. The recommended dose is 44 µg (micrograms), although a lower dose of 22 µg is available. It is recommended that therapy with Rebif is initiated at 8.8 µg, then gradually increased over the first few weeks of therapy.

Rebif is indicated for the treatment of relapsing multiple sclerosis who have had two or more acute exacerbations in hte previous two years.

Because there is no clinical evidence on the effects of Rebif beyond 4 years of treatment, it is not known how long patients should be treated for. People taking Rebif should therefore be assessed by their physicians at least every 2 years during the first 4 years of treatment. Decisions about longer-term treatment can then be made on an individual basis.

Licensed for MS in 1998, Rebif is marketed by Serono Europe Limited.

Use of this product will be determind by your neurologist according to guidance layed out in the risk-sharing scheme. More information can be found by going to www.mstrust.org.uk

More detailed prescribing information on Rebif can be found by going to www.medicines.org.uk. typing Rebif into the search box and pressing Go.

Quick Links

• Treatment rights
• Your questions
• Glossary
• Making the most of treatment
• Newly diagnosed

Supported by